{"id":"abp-234","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypocalcemia"},{"rate":null,"effect":"Osteonecrosis of the jaw"},{"rate":null,"effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL228196","moleculeType":"Small molecule","molecularWeight":"246.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABP 234 targets RANKL (receptor activator of nuclear factor kappa-B ligand), a key mediator of osteoclast differentiation and activation. By inhibiting RANKL signaling, the drug reduces bone resorption and is being developed for conditions characterized by excessive bone loss or osteoclast-mediated pathology.","oneSentence":"ABP 234 is a RANKL inhibitor that blocks osteoclast activation and bone resorption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:32.897Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Giant cell tumor of bone"},{"name":"Bone metastases"}]},"trialDetails":[{"nctId":"NCT06430866","phase":"PHASE3","title":"Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-09-12","conditions":"Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)","enrollment":154},{"nctId":"NCT06311721","phase":"PHASE3","title":"A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2024-09-09","conditions":"Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","enrollment":315}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ABP 234","genericName":"ABP 234","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABP 234 is a RANKL inhibitor that blocks osteoclast activation and bone resorption. Used for Giant cell tumor of bone, Bone metastases.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}